Which Beta-Blocker While Graves’ Disease Is Still Being Treated
A single patient whose new atrial fibrillation is being rate-controlled by a drug chosen before anyone confirmed why her heart rate wouldn't come down, and the diagnosis that answered that question has reopened the drug choice.
H.V., a 44-year-old woman, sells residential real estate, a job built around long days showing houses and even longer evenings on the phone with clients — a pace she'd maintained without difficulty until three weeks ago, when a persistent racing heartbeat sent her to urgent care between showings. She was started on metoprolol tartrate that same visit, before anyone had worked out why a healthy, physically active woman had suddenly developed a heart rate that wouldn't sit still.
The answer arrived a week later: Graves' disease, with a suppressed TSH and markedly elevated free T4, and an ECG in the same week confirming new-onset atrial fibrillation with a resting rate still sitting in the 130s despite her metoprolol. She has no prior cardiac history and no other significant medical problems. Methimazole was started to bring her thyroid hormone down, but definitive treatment — radioactive iodine, surgery, or continued antithyroid drugs — is still being worked out with endocrinology, which means her rate-control plan has to hold for weeks, not days, while that larger decision gets made.
The contested part of her case is specifically pharmacological: propranolol's peripheral inhibition of the enzyme that converts T4 to the more active T3 is real and measurable, reducing circulating T3 by a documented margin in some studies, but whether that translates into a meaningfully better outcome than adequate rate control with any beta-blocker is exactly where the literature splits. Hyperthyroidism itself complicates the comparison further, since the increased metabolic clearance that applies to essentially all these drugs in a thyrotoxic patient means the real question may be less about which beta-blocker than about whether either one has actually been dosed high enough yet to judge fairly.
Rate control while the bigger decision is still pending
I'd switch her to propranolol specifically because of what it does beyond rate control — it inhibits peripheral conversion of T4 to the more active T3, on top of its beta-blocking effect, and there's real clinical literature specifically describing propranolol as preferable to cardioselective agents in thyrotoxicosis-driven atrial fibrillation for exactly that reason. It's also the agent of choice if her disease worsens toward thyroid storm, so starting it now means we aren't switching drugs again under worse circumstances.
I'd want to be precise about how much weight that deiodinase effect actually deserves, because the standard references describing it call it “of minor therapeutic value” and note that other beta-blockers with longer half-lives are considered equally effective for the actual rate-control job. Her current rate isn't controlled, which is a real problem — but the fix for an inadequately dosed metoprolol is more metoprolol. Hyperthyroid patients clear these drugs faster than usual and often need higher-than-typical doses; we may not have actually reached her effective dose yet.
I'm not disputing that literature exists arguing for propranolol — I'm saying it's genuinely contested, not settled, and switching drugs isn't free when uptitrating the one she's already tolerating is the more conservative next step.
Given how contested that specific question is, and that switching drugs mid-diagnosis adds one more variable while endocrinology is still working out her definitive treatment plan, I'd rather change one thing at a time — uptitrate metoprolol now, and keep propranolol explicitly on the table if rate control still isn't adequate at a higher dose.
Metoprolol tartrate dose increased this visit rather than switched to propranolol; methimazole continues unchanged. Repeat heart rate check in one week, with thyroid function rechecked on the same timeline. Anticoagulation was considered and not started: her CHA2DS2-VASc score is 1 on female sex alone, which current guidance treats as a risk modifier rather than a standalone indication, and thyrotoxicosis does not itself add a point.
The current regimen continues as-is, and the propranolol question doesn't need to be revisited.
Propranolol becomes the next step, chosen specifically for the deiodinase rationale rather than as a generic alternative.
The endocrinologist and the pharmacologist never resolved which reading of the propranolol literature is correct for her specifically — the plan proceeds on the more conservative option while leaving the contested one explicitly available, rather than either side's argument being declared the winner.